PRMT5 Recombinant Monoclonal Antibody

1. Expression of PRMT5 was significantly increased in human gastric cancer (GC) tissues compared with normal gastric mucosa. Multiple evidences suggested that PRMT5 repressed transcription of tumor suppressor IRX1 via recruitment of DNMT3A on promoter. PMID: 29802960
2. PRMT5 may play a role from early oncogenesis through to the progression of oral squamous cell carcinoma , particularly in the aggressive mode of stromal invasion PMID: 29603824
3. he phosphorylation of the MP inhibitory MYPT1(T850) and the regulatory PRMT5(T80) residues as well as the symmetric dimethylation of H2A/4 were elevated in human hepatocellular carcinoma and in other types of cancers. PMID: 28074910
4. The polymerase-associated factor complex regulates Prmt5 to facilitate leukemic progression and is a potential therapeutic target for acute myeloid leukemias. PMID: 28945229
5. our results indicated that PRMT5 overexpression in hepatocellular carcinoma (HCC)and colon cancer cells contributed to their acquisition of aggressive characteristics, such as invasiveness, thus presenting a promising therapeutic target for the treatment of these diseases PMID: 29749478
6. PRMT5 as a key in vitro and in vivo regulator of breast cancer stem cells proliferation. PRMT5 epigenetically regulates FOXP1. PMID: 29262329
7. Protein arginine methyltransferase 5 (PRMT5) was identified to be responsible for Eno-1 methylation. Overexpression of PRMT5 and caveolin-1 enhanced levels of membrane-bound extracellular Eno-1 and, conversely, pharmacological inhibition of PRMT5 attenuated Eno-1 cell-surface localization. PMID: 29501774
8. A 3.7 A structure of PRMT5, solved in complex with regulatory binding subunit MEP50 (methylosome associated protein 50, WDR77, p44), by single particle (SP) cryo-Electron Microscopy (cryo-EM) using micrographs of particles that are visibly crowded and aggregated. The catalytic PRMT5 subunits form a core tetramer and the MEP50 subunits are arranged peripherally in complex with the PRMT5 N-terminal domain. PMID: 29518110
9. These kinetic studies suggest a biochemical explanation for the interplay between PRMT5- and PRMT7-mediated methylation of the same substrate at different residues and also suggest a general model for regulation of PRMTs. PMID: 28874563
10. Data indicate the significant potential of PRMT5 as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). PMID: 28591716
11. PRMT5 inhibited the interaction between CDK4 and CDKN2A and then activated the CDK4-RB-E2F pathway in hepatocellular carcinoma cells under glucose induction. PMID: 27708221
12. Data suggest that the protein arginine methyltransferase 5 (PRMT5)-E2F1 transcription factor (E2F-1) pathway may act as a common target for exogenous lectins including Anguilla japonica lectin 1 (AJL1), and the cellular response to exogenous AJL1 may suggest a novel agent for cancer gene therapy. PMID: 26990556
13. These results could be helpful in discovering new potent and specific inhibitors of PRMT5, as well as in designing mutant residue assay to modulate the catalytic activity of PRMT5. PMID: 29154828
14. PRMT1 inhibition prevents gastric cancer progression by downregulating eIF4E and targeting type II PRMT5. PMID: 28987382
15. Data indicate that ZNF326 is an interaction partner and substrate of the PRMT5/WDR77 complex. PMID: 28977470
16. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. PMID: 27183006
17. SFN treatment of tumors results in reduced MEP50 level and H4R3me2s formation, confirming that that SFN impacts this complex in vivo. These studies suggest that the PRMT5/MEP50 is required for tumor growth and that reduced expression of this complex is a part of the mechanism of SFN suppression of tumor formation. PMID: 28854561
18. High nuclear PRMT5 expression is associated with oropharyngeal squamous cell carcinoma. PMID: 28107179
19. High PRMT5 expression is associated with prostate cancer. PMID: 27546619
20. Results provide evidence that PRMT5 and p44 regulate gene expression of growth and anti-growth factors to promote lung tumorigenesis. PMID: 27480244
21. PRMT5 regulates internal ribosome entry site-dependent translation via methylation of hnRNP A1. PMID: 28115626
22. PRMT5 knockdown reduces growth, survival, and colony formation of chronic myelogenous leukemia CD34+ cells. PMID: 27643437
23. Methylation of RUVBL1 by the arginine methyltransferase PRMT5 is required for homologous recombination-mediated double-strand break repair by promoting TIP60-mediated histone H4K16 acetylation. PMID: 28238654
24. findings show that PRMT5 is an important modulator of CD4(+) T cell expansion; PRMT5 was transiently upregulated during maximal proliferation of mouse and human memory Th cells; data implicate PRMT5 in the regulation of adaptive memory Th cell responses PMID: 28087667
25. Results provide evidence that PRMT5 differentially regulates self-renewal, survival and proliferation of primary glioblastoma neurosphere cells (GBMNS) PMID: 27292259
26. PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes. PMID: 27860244
27. The C-terminal motif of PRMT5 is required for plasma membrane association, and loss of this switching capacity is not compatible with life. This signaling phenomenon was recently reported for the HPV E6 oncoprotein but has not yet been observed for mammalian proteins PMID: 28031468
28. our results indicate that PRMT5 may act as a putative oncogene in hepatocellular carcinoma PMID: 28101581
29. high expression of PRMT5 in primary and metastatic breast cancer lesions and indicated its function in cell proliferation, cell cycle progression, and apoptosis. PMID: 28381188
30. Study showed that PRMT5 mRNA levels were significantly higher in gastric cancer (GC) tissues and were independent of tumor depth, differentiation and lymph node metastasis. Findings indicate that PRMT5 acts as an oncogene in GC by enhancing the malignant phenotype of a cancer cell line. PMID: 27315569
31. PRMT5 as an ASK1-binding protein.PRMT5 mediates arginine methylation of ASK1. PMID: 26912789
32. methionine adenosyltransferase II alpha (MAT2A), and the arginine methyltransferase, PRMT5, as vulnerable enzymes in cells with MTAP deletion. PMID: 27068473
33. Our results indicate that PRMT5 is a marker of poor prognosis in NPC patients. PRMT5 promoted the radioresistance of NPC cells via targeting FGFR3, at least partly if not totally. PMID: 26708443
34. Data show that Omomyc protein co-localized with proto-oncogene protein c-myc (c-Myc), protein arginine methyltransferase 5 (PRMT5) and histone H4 H4R3me2s-enriched chromatin domains. PMID: 26563484
35. PRMT5 expression was upregulated during HTLV-1-mediated T-cell transformation. PMID: 26729154
36. Increased PRMT5 activity enhanced acute myeloid leukemia growth. PMID: 26536822
37. arginine residues within the third intracellular loop of the D2 dopamine receptor were methylated by protein arginine methyltransferase 5 (PRMT5) PMID: 26554819
38. high nuclear expression of Protein arginine methyltransferase-5 is a potentially useful marker for estimating submucosal invasion of early colorectal carcinomas in endoscopically resected specimens PMID: 26248553
39. Findings provide new evidence that PRMT5 plays an important role in CRC pathogenesis through epigenetically regulating arginine methylation of oncogenes such as eIF4E and FGFR3. PMID: 26078354
40. PRMT5-induced methylation prevented phosphorylation of SREBP1a on S430 by GSK3beta PMID: 26759235
41. PRMT5 plays an important role in human hepatocellular carcinoma growth via the downregulation of beta-catenin PMID: 26541651
42. PRMT5 gene is silencing gene expression by histone arginine methylation in keratinocytes. PMID: 26763441
43. PRMT5 co-localizes with RASSF1A on stabilized microtubules.RASSF1A promotes the translocation of cytosolic PRMT5 to microtubules. PMID: 26482848
44. UHRF1 could form a complex with PRMT5 to contribute to the endometrial carcinogenesis. PMID: 26597461
45. these findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common "passenger" genomic alteration. PMID: 26912360
46. methylthioadenosine accumulation in 5-methylthioadenosine phosphorylase-deleted cancers creates a hypomorphic PRMT5 state that is selectively sensitized toward further PRMT5 inhibition. PMID: 26912361
47. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease. PMID: 25927346
48. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers PMID: 25582697
49. The novel PRMT5S likely contributes to the observed diverse effects of PRMT5 in cells. PMID: 26151339
50. These studies implicate PRMT5 in a novel mode of MYCN post-translational regulation. PMID: 25475372

显示更多

收起更多

HGNC: 10894

OMIM: 604045

KEGG: hsa:10419

STRING: 9606.ENSP00000319169

UniGene: Hs.367854